Uptravi (Selexipag) Patent Expiration, LOE Window & CMS Spending

Uptravi (Selexipag) by Johnson & Johnson: FDA Orange Book core substance LOE 2031-02-01 (last listed 2037-06-01), 2 AB generics, $908.8M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN207947 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-02-01
Last Listed Patent or Exclusivity Date2037-06-01
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$908.8M
2024 Medicare Part D Spend$908.8M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)21 WAC filings (max 20.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.